Literature DB >> 30209392

The genetic basis and cell of origin of mixed phenotype acute leukaemia.

Thomas B Alexander1,2, Zhaohui Gu3, Ilaria Iacobucci3, Kirsten Dickerson3, John K Choi3, Beisi Xu4, Debbie Payne-Turner3, Hiroki Yoshihara3, Mignon L Loh5, John Horan6, Barbara Buldini7, Giuseppe Basso7, Sarah Elitzur8, Valerie de Haas9, C Michel Zwaan9,10, Allen Yeoh11, Dirk Reinhardt12, Daisuke Tomizawa13, Nobutaka Kiyokawa14, Tim Lammens15, Barbara De Moerloose15, Daniel Catchpoole16, Hiroki Hori17, Anthony Moorman18, Andrew S Moore19, Ondrej Hrusak20, Soheil Meshinchi21,22, Etan Orgel23, Meenakshi Devidas24, Michael Borowitz25, Brent Wood26, Nyla A Heerema27, Andrew Carrol28, Yung-Li Yang29, Malcolm A Smith30, Tanja M Davidsen31, Leandro C Hermida32, Patee Gesuwan32, Marco A Marra33, Yussanne Ma33, Andrew J Mungall33, Richard A Moore33, Steven J M Jones33, Marcus Valentine34, Laura J Janke3, Jeffrey E Rubnitz1, Ching-Hon Pui1, Liang Ding4, Yu Liu4, Jinghui Zhang4, Kim E Nichols1, James R Downing3, Xueyuan Cao35, Lei Shi35, Stanley Pounds35, Scott Newman4, Deqing Pei35, Jaime M Guidry Auvil32, Daniela S Gerhard32, Stephen P Hunger36, Hiroto Inaba37, Charles G Mullighan38.   

Abstract

Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid and lymphoid features, limited genetic characterization, and a lack of consensus regarding appropriate therapy. Here we show that the two principal subtypes of MPAL, T/myeloid (T/M) and B/myeloid (B/M), are genetically distinct. Rearrangement of ZNF384 is common in B/M MPAL, and biallelic WT1 alterations are common in T/M MPAL, which shares genomic features with early T-cell precursor acute lymphoblastic leukaemia. We show that the intratumoral immunophenotypic heterogeneity characteristic of MPAL is independent of somatic genetic variation, that founding lesions arise in primitive haematopoietic progenitors, and that individual phenotypic subpopulations can reconstitute the immunophenotypic diversity in vivo. These findings indicate that the cell of origin and founding lesions, rather than an accumulation of distinct genomic alterations, prime tumour cells for lineage promiscuity. Moreover, these findings position MPAL in the spectrum of immature leukaemias and provide a genetically informed framework for future clinical trials of potential treatments for MPAL.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30209392      PMCID: PMC6195459          DOI: 10.1038/s41586-018-0436-0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  65 in total

1.  BLAT--the BLAST-like alignment tool.

Authors:  W James Kent
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

2.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Authors:  Christian Flotho; Elaine Coustan-Smith; Deqing Pei; Shotaro Iwamoto; Guangchun Song; Cheng Cheng; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

3.  Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Authors:  Marc R Mansour; Brian J Abraham; Lars Anders; Alla Berezovskaya; Alejandro Gutierrez; Adam D Durbin; Julia Etchin; Lee Lawton; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Takaomi Sanda; Richard A Young; A Thomas Look
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Authors:  Richard C Harvey; Charles G Mullighan; Xuefei Wang; Kevin K Dobbin; George S Davidson; Edward J Bedrick; I-Ming Chen; Susan R Atlas; Huining Kang; Kerem Ar; Carla S Wilson; Walker Wharton; Maurice Murphy; Meenakshi Devidas; Andrew J Carroll; Michael J Borowitz; W Paul Bowman; James R Downing; Mary Relling; Jun Yang; Deepa Bhojwani; William L Carroll; Bruce Camitta; Gregory H Reaman; Malcolm Smith; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

6.  Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Authors:  Richard T Williams; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-17       Impact factor: 11.205

7.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

8.  Distinct routes of lineage development reshape the human blood hierarchy across ontogeny.

Authors:  Faiyaz Notta; Sasan Zandi; Naoya Takayama; Stephanie Dobson; Olga I Gan; Gavin Wilson; Kerstin B Kaufmann; Jessica McLeod; Elisa Laurenti; Cyrille F Dunant; John D McPherson; Lincoln D Stein; Yigal Dror; John E Dick
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Design and analysis of ChIP-seq experiments for DNA-binding proteins.

Authors:  Peter V Kharchenko; Michael Y Tolstorukov; Peter J Park
Journal:  Nat Biotechnol       Date:  2008-11-16       Impact factor: 54.908

View more
  81 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

2.  Context-specific tumor suppression by PHF6.

Authors:  Jennifer J Trowbridge
Journal:  Blood       Date:  2019-04-18       Impact factor: 22.113

Review 3.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

4.  Germline deletion of ETV6 in familial acute lymphoblastic leukemia.

Authors:  Evadnie Rampersaud; David S Ziegler; Ilaria Iacobucci; Debbie Payne-Turner; Michelle L Churchman; Kasmintan A Schrader; Vijai Joseph; Kenneth Offit; Katherine Tucker; Rosemary Sutton; Meera Warby; Georgia Chenevix-Trench; David G Huntsman; Maria Tsoli; R Scott Mead; Chunxu Qu; Vasiliki Leventaki; Gang Wu; Charles G Mullighan
Journal:  Blood Adv       Date:  2019-04-09

Review 5.  How advanced are we in targeting novel subtypes of ALL?

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2019-10-18       Impact factor: 3.020

Review 6.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

7.  Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.

Authors:  Eman O Rasekh; Randa Osman; Dalia Ibraheem; Youssef Madney; Enas Radwan; Abdallah Gameel; Ahmed Abdelhafiz; Azza Kamel; Sally Elfishawi
Journal:  Ann Hematol       Date:  2020-11-23       Impact factor: 3.673

8.  PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.

Authors:  Helen M McRae; Alexandra L Garnham; Yifang Hu; Matthew T Witkowski; Mark A Corbett; Mathew P Dixon; Rose E May; Bilal N Sheikh; William Chiang; Andrew J Kueh; Tan A Nguyen; Kevin Man; Renee Gloury; Brandon J Aubrey; Antonia Policheni; Ladina Di Rago; Warren S Alexander; Daniel H D Gray; Andreas Strasser; Edwin D Hawkins; Stephen Wilcox; Jozef Gécz; Axel Kallies; Matthew P McCormack; Gordon K Smyth; Anne K Voss; Tim Thomas
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

9.  How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children.

Authors:  David T Teachey; David O'Connor
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

10.  PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Authors:  Zhaohui Gu; Michelle L Churchman; Kathryn G Roberts; Ian Moore; Xin Zhou; Joy Nakitandwe; Kohei Hagiwara; Stephane Pelletier; Sebastien Gingras; Hartmut Berns; Debbie Payne-Turner; Ashley Hill; Ilaria Iacobucci; Lei Shi; Stanley Pounds; Cheng Cheng; Deqing Pei; Chunxu Qu; Scott Newman; Meenakshi Devidas; Yunfeng Dai; Shalini C Reshmi; Julie Gastier-Foster; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; William L Carroll; Patrick A Zweidler-McKay; Karen R Rabin; Leonard A Mattano; Kelly W Maloney; Alessandro Rambaldi; Orietta Spinelli; Jerald P Radich; Mark D Minden; Jacob M Rowe; Selina Luger; Mark R Litzow; Martin S Tallman; Janis Racevskis; Yanming Zhang; Ravi Bhatia; Jessica Kohlschmidt; Krzysztof Mrózek; Clara D Bloomfield; Wendy Stock; Steven Kornblau; Hagop M Kantarjian; Marina Konopleva; Williams E Evans; Sima Jeha; Ching-Hon Pui; Jun Yang; Elisabeth Paietta; James R Downing; Mary V Relling; Jinghui Zhang; Mignon L Loh; Stephen P Hunger; Charles G Mullighan
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.